Alkermes PLC (ALKS) Director Sells $94,840.00 in Stock
Alkermes PLC (NASDAQ:ALKS) Director Paul J. Mitchell sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 4th. The shares were sold at an average price of $47.42, for a total value of $94,840.00. Following the completion of the sale, the director now owns 10,000 shares in the company, valued at $474,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Alkermes PLC (NASDAQ:ALKS) opened at 46.15 on Wednesday. Alkermes PLC has a 52-week low of $27.14 and a 52-week high of $80.71. The stock’s market capitalization is $6.99 billion. The company has a 50-day moving average price of $46.88 and a 200-day moving average price of $43.71.
Alkermes PLC (NASDAQ:ALKS) last issued its quarterly earnings results on Thursday, July 28th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.09. Alkermes PLC had a negative return on equity of 14.18% and a negative net margin of 41.19%. The firm had revenue of $195.20 million for the quarter, compared to the consensus estimate of $174.15 million. During the same period in the prior year, the business posted ($0.09) earnings per share. The company’s revenue for the quarter was up 28.9% on a year-over-year basis. On average, equities analysts anticipate that Alkermes PLC will post ($0.12) earnings per share for the current year.
Several large investors have recently modified their holdings of ALKS. LS Investment Advisors LLC increased its stake in shares of Alkermes PLC by 23.6% in the second quarter. LS Investment Advisors LLC now owns 2,846 shares of the company’s stock valued at $123,000 after buying an additional 544 shares during the last quarter. Glenmede Trust Co. NA increased its stake in shares of Alkermes PLC by 2,458.1% in the second quarter. Glenmede Trust Co. NA now owns 3,300 shares of the company’s stock valued at $142,000 after buying an additional 3,171 shares during the last quarter. Mn Services Vermogensbeheer B.V. increased its stake in shares of Alkermes PLC by 3.4% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 3,829 shares of the company’s stock valued at $149,000 after buying an additional 127 shares during the last quarter. Strs Ohio increased its stake in shares of Alkermes PLC by 29.6% in the second quarter. Strs Ohio now owns 4,050 shares of the company’s stock valued at $175,000 after buying an additional 925 shares during the last quarter. Finally, Independent Portfolio Consultants Inc. acquired a new stake in shares of Alkermes PLC during the second quarter valued at $179,000. Hedge funds and other institutional investors own 95.13% of the company’s stock.
A number of equities analysts have issued reports on the company. Leerink Swann assumed coverage on Alkermes PLC in a report on Tuesday. They set an “outperform” rating and a $57.00 price target on the stock. Citigroup Inc. increased their price target on Alkermes PLC from $44.00 to $53.00 and gave the stock a “neutral” rating in a report on Tuesday, September 27th. Zacks Investment Research cut Alkermes PLC from a “buy” rating to a “hold” rating in a report on Tuesday, September 27th. Cowen and Company restated a “buy” rating on shares of Alkermes PLC in a report on Friday, September 23rd. Finally, Morgan Stanley restated a “sell” rating and set a $41.00 price target on shares of Alkermes PLC in a report on Friday, September 2nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $55.90.
Alkermes PLC Company Profile
Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis.
Receive News & Stock Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related stocks with our FREE daily email newsletter.